N-Acetyl Selank: The Complete Guide

N-Acetyl Selank (also written NA-Selank, Ac-Selank, NA Selank) is the N-terminally acetylated derivative of Selank, with sequence Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro (Ac-TKPRPGP). The acetyl group caps the N-terminus to reduce aminopeptidase cleavage.

Parent: Selank

• Parent sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP), where TKPR is the immune-modulating tetrapeptide tuftsin and PGP is a proline-glycine-proline cap (the same C-terminal motif used in Semax for protease resistance).
• Origin: Russian Academy of Sciences Institute of Molecular Genetics (Moscow), 1990s. Same lab pedigree as Semax.
• Russian regulatory status: Selank IS registered in Russia as a nasal solution drug for anxiety / asthenia.

The audit-critical asymmetry:

Parent Selank has substantial Russian primary literature. N-Acetyl Selank has ZERO PubMed-indexed primary literature on the N-acetylated molecule itself.

Direct PubMed searches for "N-acetyl selank," "NA-Selank," "acetyl-selank," and "Ac-TKPRPGP" all return zero records (verified 2026-05-07). NLM Supplementary Concept lookups for related identifiers return parent Selank only. This means every published paper that mentions Selank pharmacology is on the unmodified parent — not on the N-acetylated derivative sold gray-market.

Vendor / community claims of "stronger" or "longer-acting" rest on medicinal-chemistry intuition (N-terminal acetylation typically reduces aminopeptidase cleavage) plus wholesale import of parent Selank pharmacology — not on a measured head-to-head comparison.

Regulatory status:

• FDA (US): never approved (parent or N-acetyl form). Sold as research chemical.
• EMA (EU): not approved.
• Russia: parent Selank is registered as a nasal solution drug. N-Acetyl Selank is not registered separately — the regulatory authorization is for the unmodified parent.
• WADA 2026: not on the prohibited list by name. As an unapproved investigational substance, S0 (non-approved substances) catch-all may apply.

Every mechanism claim below is from the parent Selank literature. None has been measured for the N-acetylated derivative itself.

Parent Selank pharmacology (verified):

• Anxiolytic without sedation — head-to-head vs the benzodiazepines medazepam and phenazepam in Russian clinical work. Zozulya 2008 (PMID 18454096) compared Selank vs medazepam in generalized anxiety / neurasthenia (n=62). Medvedev 2014 (PMID 25176261) compared vs phenazepam, with reported 1-week post-dose effect persistence.
• GABAergic gene expression modulation — Volkova 2016 (PMID 26924987): Selank modulates GABAergic gene expression in rat frontal cortex.
• BDNF upregulation — Inozemtseva 2008 (PMID 18841804): intranasal Selank increased hippocampal BDNF mRNA and protein in rats.
• Enkephalin-degrading peptidase inhibition — Kost 2001 (PMID 11550013): Selank inhibits enkephalin-degrading peptidases (IC50 ~15–20 µM). This may underlie part of the anxiolytic and analgesic profile.
• Th1/Th2 cytokine shift — Uchakina 2008 (PMID 18577961): IL-6 mRNA suppression in PBMC; tuftsin-related immune modulation.
• Anticoagulant-like activity of proline-rich peptides — Bakaeva 2006 (PMID 16634437): proline-containing peptides including Selank.
• Negative result worth flagging — Filatova 2017 (PMID 28293190): IMR-32 cells in vitro; Selank-alone showed no protective effect (negative result; balances the positive in vivo / clinical literature).

What the N-acetyl modification is hypothesized to do:

By analogy to other N-acetylated peptides (including N-acetyl Semax):

• Reduced aminopeptidase cleavage at the N-terminus → longer plasma residence.
• Possibly improved BBB penetration via altered hydrophobicity / charge profile.
• Vendor framing: "stronger and longer-acting Selank."

None of these has been measured for N-Acetyl Selank specifically. The claim is extrapolated from parent Selank PK + N-terminal-acetylation chemistry, not from published trials.

Claim	Source	What it actually measured
Anxiolytic effect comparable to benzodiazepines	Zozulya 2008 (PMID 18454096); Medvedev 2014 (PMID 25176261)	Parent Selank only. Russian clinical trials of unmodified TKPRPGP.
GABAergic gene expression modulation	Volkova 2016 (PMID 26924987)	Parent Selank only. Rat frontal cortex.
BDNF upregulation in hippocampus	Inozemtseva 2008 (PMID 18841804)	Parent Selank only. Rat hippocampus, intranasal.
Enkephalin-degrading peptidase inhibition	Kost 2001 (PMID 11550013)	Parent Selank only. In vitro.
Immune cytokine shift (Th2→Th1)	Uchakina 2008 (PMID 18577961)	Parent Selank only.
"Longer half-life vs Selank"	None — vendor / community framing	Not measured for N-Acetyl Selank. Pure medicinal-chemistry intuition.
"Stronger anxiolytic effect"	None	Not measured. Community report / vendor framing only.
Human PK / safety of N-Acetyl Selank	None	No published study.

Honest framing for any claim: if the source is a parent-Selank paper, label it "(parent Selank — extrapolated)" and don't silently import it as if it measured the derivative.

No published trial of N-Acetyl Selank exists. The dosing below is community / vendor convention extrapolated from parent Selank protocols.

Parameter	Common Range
Dose (intranasal)	250–750 µg/spray, 1–3 sprays/day; total ~250–2250 µg/day
Dose (SC, less common)	250–500 µg/day
Frequency	Daily, with morning preference (community)
Cycle length	2–6 weeks (community); parent Selank trials were similar duration
Route	Intranasal most common (mirrors Russian-registered Selank formulation); SC less common

The "longer half-life" framing is sometimes used to justify less-frequent dosing (every-other-day or twice-weekly), but no published PK study supports specific intervals for the N-acetylated form.

For a typical 5 mg lyophilized vial:

• Add 2 mL bacteriostatic water → 2.5 mg/mL.
• On a U-100 insulin syringe, 1 unit = 25 µg.
• For a 500 µg intranasal dose — 0.2 mL (20 units).

Storage:

• Lyophilized: stable at room temperature short-term; refrigerate longer-term.
• Reconstituted: refrigerate. Use within 28 days.
• Nasal solution: protect from light; refrigerated.

For the full reconstitution protocol, see the Bacteriostatic Water guide.

No published human safety data on N-Acetyl Selank. No FAERS, EudraVigilance, or Yellow Card entries.

Parent Selank safety profile (extrapolated):

• Generally well-tolerated in Russian clinical trials.
• Mild irritability or insomnia reported with later-day dosing (community).
• Nasal irritation with intranasal route.
• Headache, transient.
• No abuse potential, no withdrawal pattern reported (one of the framings that motivated parent Selank as a benzodiazepine alternative).

Theoretical concerns specific to N-acetylation:

• If the N-acetyl group really does extend half-life as claimed, accumulation effects with chronic dosing could differ from parent Selank.
• None of this is characterized in published research.

• Pregnancy / breastfeeding — no safety data on either parent or N-acetyl form; default contraindication.
• Concurrent benzodiazepines or sedative-hypnotics — theoretical additive GABA-system effects; physician supervision recommended.
• Concurrent SSRIs / SNRIs — no documented interaction, but uncharacterized.
• Active major depressive disorder requiring evidence-based treatment — parent Selank trials were in anxiety / asthenia, not severe MDD.
• Athletes subject to anti-doping testing — consult your governing body. WADA S0 catch-all may apply.

Compound	Difference from N-Acetyl Selank
Selank (parent)	The unmodified parent: Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). All published clinical and preclinical evidence is on the parent. Russian-registered drug. N-Acetyl form is a derivative with no published trials.
N-Acetyl Semax	Sister N-acetyl modification on a different parent (Semax = MEHFPGP, ACTH(4-7) analog with PGP cap). Same modification logic, different parent peptide, different mechanism.
N-Acetyl Semax Amidate	Variant: N-Acetyl Semax with C-terminal amidation. Different molecule from N-Acetyl Semax and unrelated to N-Acetyl Selank.
Tuftsin	The TKPR tetrapeptide that forms the immune-modulating core of Selank. Standalone tuftsin is studied separately for immune activation. Selank wraps tuftsin with a PGP cap for stability.
Semax	Parent ACTH(4-7) analog from the same Russian Academy lab. Different sequence, different mechanism (BDNF/NGF upregulation; nootropic).
Cerebrolysin	Porcine brain extract; multi-component; different family entirely.
MIF-1	Different mechanism (D2 PAM); different research lineage.

Vendor identity confidence:

Research-chem vendors selling "N-Acetyl Selank" may be supplying Ac-TKPRPGP, parent Selank mislabeled, or other vendor-specific variants. There is no industry-standard verification — no monograph, no reference standard. Buyer-beware framing applies.